MiNK adopts Executive Change of Control Plan; stockholders elect directors, ratify KPMG

MiNK Therapeutics, Inc.

Board approved Executive Change of Control Plan providing 50% time-based equity vesting upon a change of control.
Plan includes severance: 12 months salary plus target/actual bonus, COBRA coverage, and full equity vesting for qualifying terminations after a change of control.
Stockholders re-elected Peter Behner, Jennifer Buell, and Ulf Wiinberg as Class I directors at June 8 annual meeting.
Proposal to ratify KPMG as independent auditor for FY2022 approved with 28.1M votes for.
Plan also includes non-compete and non-solicitation covenants for participating executives.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.